Aging Population and Pipeline Launches Fuel Rapid Growth in Ophthalmic Pharma MarketDublin, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The "Ophthalmic Drugs Market Report 2025-2035" has been added to ...

An assortment of different preservative formulations has been used in ophthalmic medicines and many of these preservatives have been linked to unwanted ocular surface side effects. Benzalkonium ...

SMi reports: Alan Franklin, CEO, ForwardVue Pharma will be presenting at the Ophthalmic Drugs conference The 4 th Annual Ophthalmic Drugs Conference taking place on the 23 rd-24 th November 2020 ...

VisiRose Inc. (”VisiRose” or the “Company”), a privately-held, clinical-stage biotechnology company developing novel ocular ...

Eye drops are the most preferred drug delivery method in the ophthalmic market, yet developing eye drop formulations targeting the retina, located in the posterior segment of the eye, remains a ...

Glaukos submitted a new drug application to the FDA for Epioxa ... closer in being able to provide keratoconus patients and the ophthalmic community with the first FDA approved, noninvasive ...

Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF ... coming after the marketing approvals for the drug in the UK and EU earlier this year. Cost-effectiveness ...

Loteprednol Etabonate Ophthalmic Gel, 0.38% (RLD Lotemax SM) had an estimated annual sale of USD 36 million in the U.S.

Catch up on the clinical trial news, updates from the United States Food and Drug Administration (FDA), and company funding ...

KNOXVILLE, Tenn., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced a $3 million seed financing round for VisiRose, Inc.

EDTA has gained use in ophthalmic solutions owing to its ability to bind metals. Therapeutically, EDTA has been used to remove calcified plaques that occur in the superficial cornea in band ...